



IFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

88

## **Jerachmiel APPELBAUM**

88

Serial No.: 10/550,681

38

I.A. Filing March 25, 2004

§

Date:

## Group Art Unit:

**For:** **PHARMACEUTICAL  
COMPOSITIONS FOR  
INHIBITING METAL...**

## § Not Yet Assigned

8

38

30

**Examiner:** Not Yet Assigned

§ Attorney Docket: 30667

• • • • • • • • • • • • • • • • • •

# Commissioner for Patents

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

Dear Sir:

This is in response to the attached Notification dated June 1, 2006, which response is being made on or before August 1, 2006, and for which no extension fee is due.

By said Notification, a sequence listing was required.

No sequence listing was included in the initial filing since none was, or is, required in this US Patent Application. Withdrawal of the Requirement is respectfully requested.

Respectfully submitted,

Martin D. Moynihan

Martin D. Moynihan  
Registration No. 40-338

Date: July 7, 2006


**UNITED STATES PATENT AND TRADEMARK OFFICE**

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/550,681	Jerachmiel (Yori) Appelbaum	30667
INTERNATIONAL APPLICATION NO.		
PCT/IL04/00279		
I.A. FILING DATE	PRIORITY DATE	
03/25/2004	03/27/2003	
<b>CONFIRMATION NO. 8344</b>		
<b>371 FORMALITIES LETTER</b>		
 OC000000019033746*		

Date Mailed: 06/01/2006

### **NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

---

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/550,681	PCT/IL04/00279	30667

FORM PCT/DO/EO/922 (371 Formalities Notice)